Annual Accounts Receivable
$111.76 M
+$2.41 M+2.20%
December 31, 2024
Summary
- As of February 23, 2025, CLB annual accounts receivable is $111.76 million, with the most recent change of +$2.41 million (+2.20%) on December 31, 2024.
- During the last 3 years, CLB annual accounts receivable has risen by +$14.93 million (+15.42%).
- CLB annual accounts receivable is now -44.49% below its all-time high of $201.32 million, reached on December 31, 2013.
Performance
CLB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$111.76 M
-$5.83 M-4.96%
December 31, 2024
Summary
- As of February 23, 2025, CLB quarterly accounts receivable is $111.76 million, with the most recent change of -$5.83 million (-4.96%) on December 31, 2024.
- Over the past year, CLB quarterly accounts receivable has stayed the same.
- CLB quarterly accounts receivable is now -46.59% below its all-time high of $209.23 million, reached on March 31, 2014.
Performance
CLB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CLB Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +2.2% | 0.0% |
3 y3 years | +15.4% | +13.0% |
5 y5 years | -15.1% | +19.9% |
CLB Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +15.4% | -5.0% | +15.4% |
5 y | 5-year | -15.1% | +34.3% | -15.1% | +34.3% |
alltime | all time | -44.5% | +34.3% | -46.6% | +34.3% |
Core Laboratories NV Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $111.76 M(+2.2%) | $111.76 M(-5.0%) |
Sep 2024 | - | $117.59 M(+1.7%) |
Jun 2024 | - | $115.64 M(+0.5%) |
Mar 2024 | - | $115.09 M(+5.2%) |
Dec 2023 | $109.35 M(+2.3%) | $109.35 M(+5.1%) |
Sep 2023 | - | $104.05 M(-2.6%) |
Jun 2023 | - | $106.82 M(-3.5%) |
Mar 2023 | - | $110.70 M(+3.5%) |
Dec 2022 | $106.91 M(+10.4%) | $106.91 M(+6.7%) |
Sep 2022 | - | $100.19 M(+1.0%) |
Jun 2022 | - | $99.18 M(+0.3%) |
Mar 2022 | - | $98.90 M(+2.1%) |
Dec 2021 | $96.83 M(+16.4%) | $96.83 M(+1.6%) |
Sep 2021 | - | $95.30 M(+2.2%) |
Jun 2021 | - | $93.22 M(+7.7%) |
Mar 2021 | - | $86.57 M(+4.1%) |
Dec 2020 | $83.19 M(-36.8%) | $83.19 M(-2.5%) |
Sep 2020 | - | $85.37 M(-15.9%) |
Jun 2020 | - | $101.46 M(-20.0%) |
Mar 2020 | - | $126.87 M(-3.6%) |
Dec 2019 | $131.58 M(+1.9%) | $131.58 M(-4.2%) |
Sep 2019 | - | $137.35 M(+1.8%) |
Jun 2019 | - | $134.90 M(+1.5%) |
Mar 2019 | - | $132.86 M(+2.9%) |
Dec 2018 | $129.16 M(-3.0%) | $129.16 M(-9.9%) |
Sep 2018 | - | $143.32 M(+5.3%) |
Jun 2018 | - | $136.15 M(-1.1%) |
Mar 2018 | - | $137.66 M(+3.4%) |
Dec 2017 | $133.10 M(+16.4%) | $133.10 M(+2.7%) |
Sep 2017 | - | $129.66 M(+0.5%) |
Jun 2017 | - | $128.98 M(+5.9%) |
Mar 2017 | - | $121.81 M(+6.5%) |
Dec 2016 | $114.33 M(-21.5%) | $114.33 M(+5.4%) |
Sep 2016 | - | $108.52 M(-2.9%) |
Jun 2016 | - | $111.75 M(-8.8%) |
Mar 2016 | - | $122.50 M(-15.9%) |
Dec 2015 | $145.69 M(-26.1%) | $145.69 M(-4.4%) |
Sep 2015 | - | $152.45 M(-1.7%) |
Jun 2015 | - | $155.11 M(-2.4%) |
Mar 2015 | - | $158.86 M(-19.4%) |
Dec 2014 | $197.16 M(-2.1%) | $197.16 M(-2.3%) |
Sep 2014 | - | $201.77 M(+0.4%) |
Jun 2014 | - | $200.99 M(-3.9%) |
Mar 2014 | - | $209.23 M(+3.9%) |
Dec 2013 | $201.32 M(+9.0%) | $201.32 M(-1.9%) |
Sep 2013 | - | $205.12 M(+7.5%) |
Jun 2013 | - | $190.87 M(-4.6%) |
Mar 2013 | - | $200.14 M(+8.3%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2012 | $184.77 M(+8.2%) | $184.77 M(+2.4%) |
Sep 2012 | - | $180.40 M(+5.7%) |
Jun 2012 | - | $170.71 M(-0.6%) |
Mar 2012 | - | $171.66 M(+0.5%) |
Dec 2011 | $170.81 M(+10.4%) | $170.81 M(+8.4%) |
Sep 2011 | - | $157.59 M(-1.6%) |
Jun 2011 | - | $160.21 M(+1.2%) |
Mar 2011 | - | $158.31 M(+2.3%) |
Dec 2010 | $154.73 M(+15.7%) | $154.73 M(+9.6%) |
Sep 2010 | - | $141.11 M(+2.6%) |
Jun 2010 | - | $137.56 M(+5.0%) |
Mar 2010 | - | $130.99 M(-2.1%) |
Dec 2009 | $133.76 M(-7.3%) | $133.76 M(+13.4%) |
Sep 2009 | - | $117.98 M(-4.8%) |
Jun 2009 | - | $123.95 M(-5.8%) |
Mar 2009 | - | $131.56 M(-8.8%) |
Dec 2008 | $144.29 M(+5.1%) | $144.29 M(-4.0%) |
Sep 2008 | - | $150.26 M(+0.7%) |
Jun 2008 | - | $149.14 M(+1.6%) |
Mar 2008 | - | $146.74 M(+6.9%) |
Dec 2007 | $137.23 M(+22.5%) | $137.23 M(-1.2%) |
Sep 2007 | - | $138.88 M(+7.9%) |
Jun 2007 | - | $128.68 M(+4.8%) |
Mar 2007 | - | $122.84 M(+9.6%) |
Dec 2006 | $112.06 M(+13.0%) | $112.06 M(+0.9%) |
Sep 2006 | - | $111.06 M(+4.3%) |
Jun 2006 | - | $106.52 M(-2.2%) |
Mar 2006 | - | $108.88 M(+9.8%) |
Dec 2005 | $99.13 M(+3.9%) | $99.13 M(+1.5%) |
Sep 2005 | - | $97.66 M(+1.0%) |
Jun 2005 | - | $96.73 M(-1.5%) |
Mar 2005 | - | $98.16 M(+2.8%) |
Dec 2004 | $95.45 M(+7.0%) | $95.45 M(+2.1%) |
Sep 2004 | - | $93.46 M(+3.0%) |
Jun 2004 | - | $90.74 M(+1.4%) |
Mar 2004 | - | $89.53 M(+0.4%) |
Dec 2003 | $89.20 M(-11.3%) | $89.20 M(-14.8%) |
Sep 2003 | - | $104.64 M(-1.1%) |
Jun 2003 | - | $105.82 M(+7.0%) |
Mar 2003 | - | $98.90 M(-1.7%) |
Dec 2002 | $100.60 M(-4.1%) | $100.60 M(+9.1%) |
Sep 2002 | - | $92.19 M(+4.7%) |
Jun 2002 | - | $88.03 M(-8.2%) |
Mar 2002 | - | $95.91 M(-8.6%) |
Dec 2001 | $104.93 M(-7.3%) | $104.93 M(-7.6%) |
Sep 2001 | - | $113.51 M(+5.0%) |
Jun 2001 | - | $108.08 M(+2.6%) |
Mar 2001 | - | $105.34 M(-7.0%) |
Dec 2000 | $113.21 M | $113.21 M |
FAQ
- What is Core Laboratories NV annual accounts receivable?
- What is the all time high annual accounts receivable for Core Laboratories NV?
- What is Core Laboratories NV annual accounts receivable year-on-year change?
- What is Core Laboratories NV quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Core Laboratories NV?
- What is Core Laboratories NV quarterly accounts receivable year-on-year change?
What is Core Laboratories NV annual accounts receivable?
The current annual accounts receivable of CLB is $111.76 M
What is the all time high annual accounts receivable for Core Laboratories NV?
Core Laboratories NV all-time high annual accounts receivable is $201.32 M
What is Core Laboratories NV annual accounts receivable year-on-year change?
Over the past year, CLB annual accounts receivable has changed by +$2.41 M (+2.20%)
What is Core Laboratories NV quarterly accounts receivable?
The current quarterly accounts receivable of CLB is $111.76 M
What is the all time high quarterly accounts receivable for Core Laboratories NV?
Core Laboratories NV all-time high quarterly accounts receivable is $209.23 M
What is Core Laboratories NV quarterly accounts receivable year-on-year change?
Over the past year, CLB quarterly accounts receivable has changed by $0.00 (0.00%)